{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:17:37Z","timestamp":1791490657560,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T00:00:00Z","timestamp":1299801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003The clinical evidence level of orphan medicines in European market authorization submissions is low: few randomized controlled trials, short treatment follow\u2010up, rarely hard clinical endpoints.<\/jats:p><jats:p>\u2022\u2003The success rate at centralized market authorization is lower for orphan drugs (62.9%) than for non\u2010orphan medicines (70.7%).<\/jats:p><jats:p>\u2022\u2003The burden of disease of rare diseases is high, affecting the lives of at least 30\u2003million patients in the European Union (EU).<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003As opposed to market authorization, orphan drugs gain reimbursement more easily than non\u2010orphan innovative drugs.<\/jats:p><jats:p>\u2022\u2003Lower quality of evidence of clinical efficacy and safety, more uncertainty on cost\u2010effectiveness and higher product prices are accepted for orphan drugs.<\/jats:p><jats:p>\u2022\u2003There is a need for collaboration between the European Commission, competent for market authorization, and the EU member states, competent for reimbursement, in assessing the therapeutic risks and benefits of orphan drugs, to reduce the evidence gap post marketing.<\/jats:p><jats:p><jats:bold>AIM<\/jats:bold> We analysed the Belgian reimbursement decisions of orphan drugs as compared with those of innovative drugs for more common but equally severe diseases, with special emphasis on the quality of clinical evidence.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> Using the National Health Insurance Agency administrative database, we evaluated all submitted orphan drug files between 2002 and 2007. A quality analysis of the clinical evidence in the orphan reimbursement files was performed. The evaluation reports of the French \u2018Haute Autorit\u00e9 de Sant\u00e9\u2019, including the five\u2010point scale parameter \u2018Service M\u00e9dical Rendu (SMR), were examined to compare disease severity. Chi\u2010squared tests (at <jats:italic>P<\/jats:italic> &lt; 0.05 significance level) were used to compare the outcome of the reimbursement decisions between orphan and non\u2010orphan innovative medicines.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> Twenty\u2010five files of orphan drugs and 117 files of non\u2010orphan drugs were evaluated. Twenty\u2010two of 25 (88%) submissions of orphan drugs were granted reimbursement as opposed to 74 of the 117 (63%) non\u2010orphan innovative medicines (<jats:italic>P<\/jats:italic>= 0.02). Only 52% of the 25 orphan drug files included a randomized controlled trial as opposed to 84% in a random control sample of 25 non\u2010orphan innovative submissions (<jats:italic>P<\/jats:italic> &lt; 0.01). The duration of drug exposure was in most cases far too short in relation to the natural history of the disease.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> Orphan drug designation predicts reimbursement despite poor quality of clinical evidence. The evidence gap at market authorization should be reduced by post\u2010marketing programmes, in which the centralized regulatory and the local reimbursement authorities collaborate in an efficient way across the European Union member states.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03877.x","type":"journal-article","created":{"date-parts":[[2010,12,8]],"date-time":"2010-12-08T08:21:20Z","timestamp":1291796480000},"page":"488-496","source":"Crossref","is-referenced-by-count":63,"title":["Access to orphan drugs despite poor quality of clinical evidence"],"prefix":"10.1111","volume":"71","author":[{"given":"Alain G.","family":"Dupont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe B.","family":"Van Wilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01666.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60872-7"},{"key":"e_1_2_6_4_2","unstructured":"Federal Drug Administration.The Orphan Drug Act.Public Law1983;97\u2013141. Available athttp:\/\/www.fda.gov\/orphan\/oda.htm(last accessed 10 January 2009)."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd919"},{"key":"e_1_2_6_6_2","first-page":"L103\/5","article-title":"Regulation (EC) No. 141\/2000 of the European Parliament and of the Council on Orphan Medicinal Products of 16 December 1999 and Commission regulation (EC) No. 847\/2000 of 27 April 2000","volume":"43","author":"European Union","year":"2000","journal-title":"Off J Eur Comm"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60873-9"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm021"},{"key":"e_1_2_6_9_2","unstructured":"European Agency for the Evaluation of Medicinal Products. Register of designated orphan medical products. Available athttp:\/\/ec.europa.eu\/enterprise\/pharmaceuticals\/register\/orphreg.htm(last accessed 10 January 2009)."},{"key":"e_1_2_6_10_2","first-page":"65","article-title":"Transparancy Dir. 89\/105\/EEC of the European Council","volume":"40","author":"Commission of the European Communities","year":"1989","journal-title":"Off J Eur Comm"},{"key":"e_1_2_6_11_2","volume-title":"Study on Orphan Drugs. Overview of the Conditions for Marketing Orphan Drugs in Europe","author":"Alcimed","year":"2005"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-27"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00299.x"},{"key":"e_1_2_6_14_2","unstructured":"RIZIV.Rijksinstituut voor Ziekte en invaliditeitsverzekering Geneesmiddelen en andere verstrekkingen. Available athttp:\/\/inami.fgov.be\/drug\/nl\/drugs\/regelementation\/legal\u2010texts\/ar\u201020011221\/pdf\/arkb20011221\/pdf(last accessed 24 April 2010)."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2009.021"},{"key":"e_1_2_6_16_2","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 Espace Professionnels de Sant\u00e9 R\u00e9\u00e9valuation du service m\u00e9dical rendu (SMR). Available athttp:\/\/www.has\u2010sante.fr\/portail\/jcms\/c_412115\/reevaluation\u2010du\u2010service\u2010medical\u2010rendu\u2010smr(last accessed 12 November 2009)."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3079"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03369.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02579.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462307051550"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60876-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02654.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci128"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624040-00001"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7523.1016"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcl033"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/11319870-000000000-00000"},{"key":"e_1_2_6_28_2","unstructured":"European Pharmaceutical Forum.Final Conclusions and Recommendations of the Pharmaceutical Forum. Available athttp:\/\/ec.europa.eu\/pharmaforum\/(last accessed 12 November 2009)."},{"key":"e_1_2_6_29_2","unstructured":"KCE Federal Knowledge Centre.HTA report 112A: Beleid voor zeldzame ziekten en weesgeneesmiddelen. Available athttp:\/\/www.kce.fgov.be\/index_nl.aspx?SGREF=5272&CREF=13645(last accessed 24 April 2010)."},{"key":"e_1_2_6_30_2","unstructured":"RIZIV.Rijksinstituut voor Ziekte en Invaliditeitsverzekering Geneesmiddelen en andere verstrekkingen. Available athttp:\/\/www.riziv.fgov.be\/drug\/nl\/drugs\/orphan_drugs\/pdf\/03\u2010nl.pdf\/(last accessed 24 April 2010)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03877.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03877.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:18:07Z","timestamp":1697429887000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03877.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03877.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03877.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,11]]}}}